USFDA inspection at Somerset facility of Lupin Ltd

The U.S. FDA has concluded an inspection at Lupin Ltd's manufacturing facility located in Somerset, New Jersey, U.S.A. The inspection was conducted from April 13, 2026 to April 17, 2026 and closed with the issuance of a Form-483 with three observations.

The company will address the observations and respond to the U.S. FDA within the stipulated timeframe. The company is committed to be compliant with CGMP standards across all its facilities.

Shares of Lupin Limited was last trading in BSE at Rs. 2324.25 as compared to the previous close of Rs. 2326.50. The total number of shares traded during the day was 39022 in over 2248 trades.

The stock hit an intraday high of Rs. 2334.15 and intraday low of 2302.60. The net turnover during the day was Rs. 90557929.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals USFDA Inspection Form483 SomersetFacility 3Observations